The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Targeted Therapy in Pulmonary Hypertension

Pathway-specific therapy for pulmonary arterial hypertension (PAH)

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Targeted Therapy in Pulmonary Hypertension?

Pulmonary arterial hypertension (PAH, Group 1) is a progressive disease characterized by pulmonary vasculopathy with mean pulmonary artery pressure ≥20 mmHg, pulmonary vascular resistance ≥2 Wood units, and pulmonary capillary wedge pressure ≤15 mmHg by right heart catheterization. Untreated, median survival is 2.8 years.

Three molecular pathways drive PAH and are therapeutic targets: 1) Endothelin pathway — endothelin receptor antagonists (ERAs: bosentan, ambrisentan, macitentan) block vasoconstriction; 2) Nitric oxide-cGMP pathway — phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and soluble guanylate cyclase stimulators (riociguat) enhance vasodilation; 3) Prostacyclin pathway — prostanoids (epoprostenol IV, treprostinil SC/IV/inhaled/oral, iloprost inhaled) and prostacyclin receptor agonists (selexipag) provide vasodilation and antiproliferation.

Modern management is risk-stratified using ESC/ERS criteria (functional class, 6MWT, BNP/NT-proBNP, hemodynamics, echo, biomarkers) at baseline and follow-up. Initial dual oral combination (ERA plus PDE5i) is recommended for most low/intermediate risk patients, with triple therapy for high-risk patients. Treatment escalation is guided by inability to achieve or maintain low-risk status. Lung transplantation is considered for failure of triple therapy. Modern era survival has improved to 5-year >70% in many specialty centers.

Symptoms

Progressive exertional dyspnea
Fatigue and decreased exercise tolerance
Syncope or presyncope (especially exertional)
Chest pain or pressure
Lower extremity edema
Palpitations and arrhythmias
Right heart failure signs (elevated JVP, hepatomegaly, ascites)

Risk Factors

Idiopathic or heritable PAH
Connective tissue disease (especially systemic sclerosis)
Congenital heart disease (Eisenmenger)
HIV infection
Portal hypertension
Drug/toxin-induced (anorexigens, methamphetamine)
Schistosomiasis

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Unexplained progressive dyspnea on exertion
  • Syncope or pre-syncope with activity
  • Connective tissue disease with new dyspnea
  • Right heart failure signs without left heart cause
  • Family history of PAH
  • Worsening symptoms during established PAH treatment
  • Pre-pregnancy counseling in known PAH (high mortality risk)

Treatment Methods

01
Right heart catheterization confirmation and vasoreactivity testing
02
Risk stratification using ESC/ERS criteria
03
Initial dual oral combination (ambrisentan/macitentan + tadalafil/sildenafil)
04
Add prostacyclin pathway agent for high-risk or progression (selexipag, parenteral prostanoids)
05
Calcium channel blockers only for vasoresponders (5%)
06
Supportive care: diuretics, oxygen, anticoagulation in select cases
07
Lung transplantation referral for refractory disease

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.